Disparities in the Use of Programmed Death 1 Immune Checkpoint Inhibitors
O'Connor JM, Seidl‐Rathkopf K, Torres AZ, You P, Carson KR, Ross JS, Gross CP. Disparities in the Use of Programmed Death 1 Immune Checkpoint Inhibitors. The Oncologist 2018, 23: 1388-1390. PMID: 30012876, PMCID: PMC6291337, DOI: 10.1634/theoncologist.2017-0673.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerAnti-PD1 agentsAnti-PD1 treatmentImmune checkpoint inhibitorsCheckpoint inhibitorsDeath-1 immune checkpoint inhibitorPrior anticancer therapyDeath protein 1Cell lung cancerCommunity-based cohortAdvanced-stage cancerRenal cell carcinomaSex-based disparitiesSystemic treatmentCell carcinomaLung cancerMultivariable modelObservational studyHigher oddsStage cancerRace-based disparitiesPatient careAnticancer therapyProtein 1Patients